{
    "clinical_study": {
        "@rank": "11738", 
        "arm_group": [
            {
                "arm_group_label": "Treatment C: Prototype 3", 
                "arm_group_type": "Experimental", 
                "description": "OZ439 800 mg and piperaquine phosphate 960 mg as powder in bottle"
            }, 
            {
                "arm_group_label": "Treatment B: Prototype 2", 
                "arm_group_type": "Experimental", 
                "description": "OZ439 800 mg and piperaquine phosphate 960 mg as powder in bottle"
            }, 
            {
                "arm_group_label": "Treatment A: Prototype 1:", 
                "arm_group_type": "Experimental", 
                "description": "OZ439 800 mg and piperaquine phosphate 960 mg as powder in bottle"
            }
        ], 
        "brief_summary": {
            "textblock": "A single dose study to investigate how different formulations of OZ439 and piperaquine\n      phosphate are processed by the body when taken without food"
        }, 
        "brief_title": "Open Label Study of Pharmacokinetics of Prototype Formulations of OZ439 Administered With Piperaquine Phosphate in the Fasted State to Healthy Subjects", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Malaria", 
        "condition_browse": {
            "mesh_term": "Malaria"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy males, or healthy females of non-childbearing potential ie surgically\n             sterilised or post-menopausal (amenorrhoea for at least 1 year and confirmed by a\n             follicle stimulating hormone result of \u226525 IU/mL\n\n          2. Age 18 to 55 years of age\n\n          3. Body mass index of 18.0 to 30.0 kg/m2 inclusive. Total body weight >50 kg at\n             screening\n\n          4. Willing and able to communicate and participate in the whole study\n\n          5. Must provide written informed consent\n\n          6. Must agree to use an adequate method of contraception\n\n          7. Must have liver function tests and haemoglobin within the laboratory reference range\n             at screening and Day -1\n\n          8. Must have heart trace measurements within the defined healthy limits at screening,\n             Day -1 and pre-dose\n\n        Exclusion Criteria:\n\n          1. Male subjects who have currently pregnant partners\n\n          2. Evidence or history of clinically significant oncological, pulmonary, chronic\n             respiratory, hepatic, cardiovascular, haematological, metabolic, neurological,\n             immunological, nephrological, endocrine or psychiatric disease, or current infection\n\n          3. Clinically relevant abnormalities in the heart trace including any degree of heart\n             block, including asymptomatic bundle branch block\n\n          4. Family history of sudden death or of congenital prolongation of the QTc interval or\n             known congenital prolongation of the QTc interval or any clinical condition known to\n             prolong the QTc interval\n\n          5. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia\n\n          6. Electrolyte disturbances, particularly hypokalemia, hypocalcaemia or hypomagnesaemia.\n\n          7. Any condition that could possibly affect drug absorption, such as gastrectomy or\n             diarrhoea\n\n          8. History of post-antibiotic colitis\n\n          9. History of any drug or alcohol abuse in the past 2 years prior to screening\n\n         10. Subjects who have a breath carbon monoxide reading of greater than 10 ppm at\n             screening will be excluded. Subjects who are tobacco users (including smokers and\n             users of snuff, chewing tobacco and other nicotine or nicotine-containing products)\n             must have stopped use within 90 days before screening.\n\n         11. Receipt of an investigational drug or participation in another clinical research\n             study within 90 days prior to drug administration.\n\n         12. Subjects who are study site employees, or immediate family members of a study site or\n             sponsor employee.\n\n         13. Subjects who have previously been enrolled in this study\n\n         14. Use of ANY prescription or non-prescription medications, vitamins, herbal supplements\n             or dietary supplements, including protein supplements, within 14 days prior to the\n             first dose of study drug and throughout the study, unless prior approval is granted\n             by both the investigator and the sponsor. An exception will be made for intermittent\n             use of paracetamol and hormone replacement therapy. Paracetamol at doses of, at most,\n             2 g per day or no more than 3 consecutive days or 6 non consecutive days, are allowed\n             until 24 hours before dosing with study drug. Longer exclusion periods apply for:\n\n               1. amiodarone and hydroxychloroquine (210 days)\n\n               2. monoclonal antibodies/ immunoglobulins/ other therapeutic proteins and\n                  experimental drugs for which the half-life is not known to the investigator (120\n                  days)\n\n               3. experimental drugs for which half-life is known to the investigator (5 half\n                  lives plus 14 days)\n\n               4. chloroquine, piperaquine phosphate and flunarizine (100 days)\n\n               5. fluoxetine (75 days)\n\n               6. benzodiazepines (for midazolam, lorazepam and triazolam, the exclusion period is\n                  14 days), chlorpromazine, mephenytoin, nortryptyline, phenobarbital, primidone,\n                  phenprocoumone and cytochrome P450 3A4 inducers not already mentioned, including\n                  but not restricted to, rifampin, carbamazepine, oxcarbazepine, phenytoin and St\n                  John's Wort (35 days)\n\n         15. Positive hepatitis B surface antigen, hepatitis C virus antibody or human\n             immunodeficiency virus results\n\n         16. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by\n             the investigator\n\n         17. Positive urine drug screen result at screening or admission to the clinical unit\n\n         18. History of intolerance or hypersensitivity to piperaquine or any 4-aminoquinolone, or\n             ascertained or presumptive hypersensitivity to the active principle and/or\n             formulation ingredients; history of anaphylaxis to drugs or allergic reactions in\n             general, that the investigator considers may affect the outcome of the study\n\n         19. Serious adverse reaction or serious hypersensitivity to any drug or the formulation\n             excipients\n\n         20. Presence or history of allergy requiring treatment; hayfever is allowed unless it is\n             active\n\n         21. Donation or loss of >400 mL of blood within 90 days prior to drug administration\n\n         22. Regular alcohol consumption in males >21 units per week and females >14 units per\n             week (1 unit = \u00bd pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)\n\n         23. Subjects who do not have suitable veins for multiple blood samples as assessed by the\n             investigator at screening\n\n         24. Failure to satisfy the investigator of fitness to participate for any other reason"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02083406", 
            "org_study_id": "MMV_OZ439_13_007"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment A: Prototype 1:", 
                "intervention_name": "Prototype 1: OZ439 800 mg and piperaquine phosphate 960 mg as powder in bottle", 
                "intervention_type": "Drug", 
                "other_name": "Treatment A"
            }, 
            {
                "arm_group_label": "Treatment B: Prototype 2", 
                "intervention_name": "Prototype 2: OZ439 800 mg and piperaquine phosphate 960 mg as powder in bottle", 
                "intervention_type": "Drug", 
                "other_name": "Treatment B"
            }, 
            {
                "arm_group_label": "Treatment C: Prototype 3", 
                "intervention_name": "Prototype 3: OZ439 800 mg and piperaquine phosphate 960 mg as powder in bottle", 
                "intervention_type": "Drug", 
                "other_name": "Treatment C"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Piperaquine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "malaria", 
        "lastchanged_date": "April 25, 2014", 
        "location": {
            "contact": {
                "email": "Jo.Collier@quotientclinical.com", 
                "last_name": "Joanne Collier, MBChB FFPM, Dip Stats", 
                "phone": "+44 115 974"
            }, 
            "facility": {
                "address": {
                    "city": "Nottingham", 
                    "country": "United Kingdom", 
                    "state": "Nottinghamshire", 
                    "zip": "NG11 6JS"
                }, 
                "name": "Quotient Clinical"
            }, 
            "investigator": {
                "last_name": "Jo Collier, MBChB FFPM", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "Open Label Study to Investigate the Pharmacokinetics of Prototype Formulations of OZ439 Administered With Piperaquine Phosphate in the Fasted State to Healthy Subjects", 
        "overall_contact": {
            "email": "Jo.Collier@quotientclinical.com", 
            "last_name": "Joanne Collier, MBChB FFPM", 
            "phone": "+44 (0)115 931 5507"
        }, 
        "overall_official": {
            "affiliation": "Quotient Clinical", 
            "last_name": "Jo Collier, MBChB FFPM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Area under the plasma concentration versus time curve extrapolated to infinity (AUC 0-168)", 
            "measure": "Area under the plasma concentration versus time curve (AUC 0-inf) extrapolated to infinity of OZ439 prototype formulations and PQP when co-administered in the fasted state", 
            "safety_issue": "No", 
            "time_frame": "Up to 168 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02083406"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Medicines for Malaria Venture", 
        "sponsors": {
            "collaborator": {
                "agency": "Quotient Clinical", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Medicines for Malaria Venture", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}